| Cytomegaloviral (CMV) pneumonia is a common infection after kidney transplantation, which can cause recipient death or graft rejection. It is needed to prevent and treat CMV pneumonia to get better survival rate of patient and allograft kidney.Objective:To analyze the efficacy and safety of different therapeutic strategies by investigating incidence and treatment for CMV pneumonia patients after kidney transplantation, in order to find better and scientific methods for CMV pneumonia.Methods:Data of 102 renal allograft recipients with CMV pneumonia from January 2005 to July 2008 were retrospectively analyzed. The therapeutics for 53 patients of group A included oral administration of prednisone 10 ~ 20 mg/d or methylprednisolone 40mg/d injected with no or less reduction of immunosuppressive agents. 49 patients of group B included the methylprednisolone 80-160mg/d injected with elimination of immunosuppressive agents or only half CNI. Data on effects and side effects were collected and analyzed by SPSS12.0.Results:The incidence of CMV pneumonia was 26.4% in total. The cure rate in group A was 77.4%(41/53), while in group B was 98%(48/49), which was significantly different between this two groups(p<0.05). The incidence of rejection in group A was 7.5%(4/53), while in group B was 4.1%(2/49), which was no significant difference(p>0.05). The incidence of hyperglucose in group A was 16.9%(9/53), while in group B was 22.5%(11/49), which was also no statistically different(p>0.05). Conclusions:High dose methyllprednisolone with little or without immunosuppressant was very helpful in treating CMV pneumonia, this therapeutic method can increase cure rate of CMV pneumonia without increase of rejection rate and the incidence of hyperglucose. High dose methyllprednisolone with little or without immunodepressant was better than small dose methyllprednisolone with normal immunodepressant for prevention and effective treatment of CMV pneumonia patients after kidney transplantation .
|
PDF Full Text Request